Budigalimab

Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors[1].

Product Specifications

CAS Number

[2098225-93-3]

Product Name Alternative

ABBV 181; PR 1648817

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/budigalimab.html

Purity

99.79

Solubility

10 mM in DMSO

Smiles

[Budigalimab]

Molecular Weight

(144.76 kDa)

References & Citations

[1]Powderly J, et al. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181) . Clin Transl Sci. 2021 Jan;14 (1) :277-287. |[2]Lambert SL, et al., Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab. J Immunother. 2022 Apr 1;45 (3) :167-179.